Current clinical data reveal that approximately 13% of multiple myeloma patients experience disease relapse within 12 months, yet the New England Journal of Medicine’s recent editorial questions whether this time-based threshold adequately captures the complexity of treatment response patterns. Recent studies from 2020-2025 demonstrate considerable heterogeneity: 68% of patients are long responders with progression-free survival exceeding 24 months, while 19% fall into an intermediate category of 12-24 months.
The editorial argues that these response durations alone may not capture the biological drivers that predict aggressive disease behavior. Molecular and genetic markers—such as high-risk cytogenetics and gene expression profiles—may prove more predictive of clinical outcomes than relapse timing alone. This distinction is crucial, as it could reshape treatment recommendations for the 13% of patients experiencing rapid relapse and inform risk stratification across the broader myeloma population.
Was this article helpful?
